One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Update on a silent killer: arterial hypertension
Filippo Crea
doi : 10.1093/eurheartj/ehac549
European Heart Journal, Volume 43, Issue 38, 7 October 2022, Pages 3595–3598
The mentorship programme: a new initiative at the European Heart JournalÂ
Nina Ajmone Marsan, João Cavalcante, Chiara Bucciarelli-Ducci
doi : 10.1093/eurheartj/ehac403
European Heart Journal, Volume 43, Issue 38, 7 October 2022, Pages 3599–3600
Peer review: an invaluable contribution of scientists to scienceÂ
Harry J G M Crijns
doi : 10.1093/eurheartj/ehac404
European Heart Journal, Volume 43, Issue 38, 7 October 2022, Page 3601
A tribute to our reviewersÂ
Filippo Crea, Stephan Achenbach
doi : 10.1093/eurheartj/ehac141
European Heart Journal, Volume 43, Issue 38, 7 October 2022, Pages 3602–3603
List of Reviewers 2021–2022
doi : 10.1093/eurheartj/ehac157
European Heart Journal, Volume 43, Issue 38, 7 October 2022, Pages 3604–3615
One-shot thrombolysis for the management of acute ischaemic strokeÂ
Massimo Volpe, Carlo Patrono
doi : 10.1093/eurheartj/ehac457
European Heart Journal, Volume 43, Issue 38, 7 October 2022, Pages 3616–3617
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG).
Marc Humbert, Gabor Kovacs, Marius M Hoeper, Roberto Badagliacca, Rolf M F Berger, Margarita Brida, Jørn Carlsen, Andrew J S Coats, Pilar Escribano-Subias, Pisana Ferrari, Diogenes S Ferreira, Hossein Ardeschir Ghofrani, George Giannakoulas, David G Kiely, Eckhard Mayer, Gergely Meszaros, Blin Nagavci, Karen M Olsson, Joanna Pepke-Zaba, Jennifer K Quint, Göran Rådegran, Gerald Simonneau, Olivier Sitbon, Thomy Tonia, Mark Toshner, Jean Luc Vachiery, Anton Vonk Noordegraaf, Marion Delcroix, Stephan Rosenkranz, ESC/ERS Scientific Document Group
doi : 10.1093/eurheartj/ehac237
European Heart Journal, Volume 43, Issue 38, 7 October 2022, Pages 3618–3731
Effects of a comprehensive lifestyle intervention on cardiovascular health: the TANSNIP-PESA trialÂ
Ines Garcia-Lunar, Hidde P van der Ploeg, Juan Miguel Fernández Alvira, Femke van Nassau, Jose Maria Castellano Vázquez, Allard J van der Beek, Xavier Rossello, Antonio Fernández-Ortiz, Jennifer Coffeng, Johanna M van Dongen, Jose Maria Mendiguren, Borja Ibáñez, Willem van Mechelen, Valentin Fuster
doi : 10.1093/eurheartj/ehac378
European Heart Journal, Volume 43, Issue 38, 7 October 2022, Pages 3732–3745
To investigate the effectiveness of a 3-year worksite lifestyle intervention on cardiovascular metrics and to study whether outcomes are influenced by baseline subclinical atherosclerosis (SA) by non-invasive imaging.
Primary lifestyle intervention: the challenge of making a differenceÂ
Christian Torp-Pedersen, Kathrine Kold Sørensen, Charlotte Andersson
doi : 10.1093/eurheartj/ehac376
European Heart Journal, Volume 43, Issue 38, 7 October 2022, Pages 3746–3748
Hypertensive disorders of pregnant women with heart disease: the ESC EORP ROPAC RegistryÂ
Karishma P Ramlakhan, Isabelle Malhamé, Ariane Marelli, Tobias Rutz, Sorel Goland, Arie Franx, Karen Sliwa, Uri Elkayam, Mark R Johnson, Roger Hall, Jérôme Cornette, Jolien W Roos-Hesselink
doi : 10.1093/eurheartj/ehac308
European Heart Journal, Volume 43, Issue 38, 7 October 2022, Pages 3749–3761
Hypertensive disorders of pregnancy (HDP) occur in 10% of pregnancies in the general population, pre-eclampsia specifically in 3–5%. Hypertensive disorders of pregnancy may have a high prevalence in, and be poorly tolerated by, women with heart disease.
Understanding the implications of hypertensive disorders in pregnancy in women with heart diseaseÂ
Matthew Cauldwell
doi : 10.1093/eurheartj/ehac406
European Heart Journal, Volume 43, Issue 38, 7 October 2022, Pages 3762–3764
Association between hypotension during 24 h ambulatory blood pressure monitoring and reflex syncope: the SynABPM 1 studyÂ
Giulia Rivasi, Antonella Groppelli, Michele Brignole, Davide Soranna, Antonella Zambon, Grzegorz Bilo, Martino Pengo, Bashaaer Sharad, Viktor Hamrefors, Martina Rafanelli, Giuseppe Dario Testa, Ciara Rice, Rose Anne Kenny, Richard Sutton, Andrea Ungar, Artur Fedorowski, Gianfranco Parati
doi : 10.1093/eurheartj/ehac347
European Heart Journal, Volume 43, Issue 38, 7 October 2022, Pages 3765–3776
Diagnostic criteria for ambulatory blood pressure monitoring (ABPM) in patients with suspected reflex syncope are lacking. The study hypothesis was that patients with reflex syncope have a higher prevalence of systolic blood pressure (SBP) drops on ABPM.
The extended role of 24 h ambulatory blood pressure monitoring for reflex syncopeÂ
Fabian Leys, Alessandra Fanciulli
doi : 10.1093/eurheartj/ehac409
European Heart Journal, Volume 43, Issue 38, 7 October 2022, Pages 3777–3780
Aldosterone in chronic kidney disease and renal outcomesÂ
Ashish Verma, Anand Vaidya, Sonu Subudhi, Sushrut S Waikar
doi : 10.1093/eurheartj/ehac352
European Heart Journal, Volume 43, Issue 38, 7 October 2022, Pages 3781–3791
Randomized controlled trials have demonstrated the efficacy of mineralocorticoid receptor (MR) antagonism in delaying chronic kidney disease (CKD) progression in diabetes; however, they have not investigated the role of aldosterone or whether these beneficial effects could be achieved in individuals without diabetes.
Aldosterone excess and cardiorenal risk: more common than appreciatedÂ
George L Bakris, Frederic Jaisser
doi : 10.1093/eurheartj/ehac410
European Heart Journal, Volume 43, Issue 38, 7 October 2022, Pages 3792–3793
Phenotyping the hypertensive heartÂ
Marijana Tadic, Cesare Cuspidi, Thomas H Marwick
doi : 10.1093/eurheartj/ehac393
European Heart Journal, Volume 43, Issue 38, 7 October 2022, Pages 3794–3810
Arterial hypertension remains the most frequent cardiovascular (CV) risk factor, and is responsible for a huge global burden of disease.
Targeted proteomics improves cardiovascular risk prediction in secondary prevention: the impact of statin treatment?Â
Philippe Giral
doi : 10.1093/eurheartj/ehac329
European Heart Journal, Volume 43, Issue 38, 7 October 2022, Page 3811
Different inflammatory pathways underlying cardiovascular risk in secondary preventionÂ
Nick S Nurmohamed, Jordan M Kraaijenhof, Erik S G Stroes
doi : 10.1093/eurheartj/ehac344
European Heart Journal, Volume 43, Issue 38, 7 October 2022, Page 3812
Identifies culprit of cerebral infarction: contrast echocardiography of right heart through uncommon route
Wen Xia Zhou, Hong Tang, Xin Wei
doi : 10.1093/eurheartj/ehac468
European Heart Journal, Volume 43, Issue 38, 7 October 2022, Page 3813
